Global Typhoid Vi Polysaccharide Vaccine Market Analysis 2024 – Estimated Market Size And Key Drivers

The Typhoid Vi Polysaccharide Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Typhoid Vi Polysaccharide Vaccine Market:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

According to The Business Research Company’s Typhoid Vi Polysaccharide Vaccine Global Market Report 2024, The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $4.98 billion in 2023 to $5.84 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, vaccine efficacy and safety..

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.28 billion in 2028 at a compound annual growth rate (CAGR) of 17.9%. The growth in the forecast period can be attributed to expanded immunization programs, global health policy focus, epidemiological surveillance, rising demand in travel medicine, environmental and social factors.. Major trends in the forecast period include r&d investments, regulatory support, epidemiological studies, public health awareness..

Rising typhoid prevalence is expected to propel the growth of the typhoid VI polysaccharide vaccine market going forward. Typhoid is an infection caused by the bacteria Salmonella typhi that can be fatal. It usually spreads through contaminated food or drink. Typhoid Vi polysaccharide vaccine is used to immunise adults and children aged 2 and up against typhoid fever caused by Salmonella enterica serovar Typhi, S. Typhi. For instance, in March 2021, according to a report shared by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, infections with Salmonella Typhi were believed to affect 5,700 Americans annually, with 620 of these likely to require hospitalization. Typhoid fever mostly causes between 11 and 21 million cases worldwide every year, along with 200,000 fatalities. Therefore, the rising typhoid prevalence is driving the growth of the typhoid Vi polysaccharide vaccine market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Strategic partnerships are a key trend gaining popularity in the typhoid Vi polysaccharide vaccine market. Major companies operating in the typhoid Vi polysaccharide vaccine market are entering into partnerships to strengthen their position in the typhoid Vi polysaccharide market. For instance, in July 2022, The International Vaccine Institute, a South Korea-based international organization focused on infectious diseases of global health importance such as cholera, typhoid, shigella, and salmonella, partnered with Moderna, a US-based biopharmaceutical company. This partnership led to the world’s first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

The typhoid vi polysaccharide vaccine market report table of contents includes: